A Decade in Leading BPH Care
09:00am Fri, 1st Dec, 2023
Virtual Event
Event details
How the UroLift™ System Continues to Deliver Consistent Durability With a Superior Patient Experience.
Agenda
It has been more than 10 years since the UroLift™ System first came to market, and today it is the #1 minimally invasive treatment for benign prostatic hyperplasia (BPH) in the U.S.¹ But why is it the top choice?
Tune into a 60-minute live webinar where Drs. Matt Ashley, Raj Shinghal, and Steven Kaplan will distill new and recently published clinical data on the UroLift System. What you can expect to learn during the live webinar:
• UroLift System procedure safety compared to other BPH procedures: an FDA MAUDE-based analysis²
• How newly published, real-world healthcare claims and utilization analysis debunks speculation about durability and helps physicians provide clarity on what patients can expect from minimally invasive and traditional, more invasive BPH procedures³
• The importance of patient experience as a primary consideration when counseling patients about BPH treatment options
Plus, don’t miss the live Q&A session when we will address your questions in real time.
References: 1. U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), which is in part based on Symphony Health PatientSource® 2018-21, as is and with no representations/warranties, including accuracy or completeness; 2. Shinghal R, Ashley M, Eure G (2023). Total Procedural Context is Crucial in Understanding BPH Treatment Device Safety in the FDA’s MAUDE Database. (Manuscript in preparation); 3. Kaplan, Prostate Cancer Prostatic Dis 2023; 4. Roehrborn, J Urology 2013
Consult the Instructions for Use (IFU) for more information. Rx Only.
Speakers
Matt Ashley, M.D.
Practicing urologist in Bend, ORAssociate Medical Director at Teleflex
UroLift System faculty – lectured and proctored cases worldwide
UroLift 2 System development
Published outcomes and technique for obstructive median lobe with UroLift ATC System
Raj Shinghal, M.D.
Urology Chair, Palo Alto Medical FoundationMedical School: Stanford University
Residency: Stanford University
Served on Teaching Faculty at Stanford University
Practices general urology, with a focus on BPH and stone disease
Has participated in several clinical trials for novel BPH treatments and devices for kidney stone treatment
Paid consultant of Teleflex
Steven Kaplan, M.D.
Director of the Men's Wellness Program, Mount Sinai Health SystemProfessor, Icahn School of Medicine at Mount Sinai
Internationally renowned authority and thought leader in benign prostatic hyperplasia (BPH), among other topics
Diplomat of the American Board of Urology; Fellow of the American
College of Surgeons
1,000+ publications, including 600 peer-reviewed and 570 peer-reviewed invited articles, and 90 book chapters and non-peer reviewed articles
340+ presentations in more than 35 countries; Co-author of five books
On the Editorial Board of numerous journals including Urology,
Journal of Urology, and Urology Times
Has been awarded 5 NIH grants and has received over $13 million in research funding
Registration
Talk to Your Patient About the UroLift® System Today
Patients who seek medical advice might not be fully aware of the treatment options available to them and will need appropriate information and time to make a decision. Providing materials explaining their options, that they can bring home to discuss with their loved ones will be beneficial. test
Download Patient Info Bookiet